In a phase II feasibility trial of 21 patients with recurrent/metastatic head and neck squamous cell carcinoma given metformin plus pembrolizumab (two sequencing arms), ORR was 50% (95% CI 29–71) in 18 evaluable patients; five grade 3 AEs, mainly gastrointestinal.
RCTn = 21
Zamulko et al. A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer